ARCHIVES

Sanofi: Zaltrap Price Reflects Competing Drugs In Second-Line Metastatic Colon Cancer

This article is from The Cancer Letter archive.

Vol. 38 No. 41 | November 1, 2012

Download PDF Visit The Full Archive

Related Articles

New Frederick Contract Drops Slightly From ‘75

July 11, 1975

Morale, Money Woes Hit MD Anderson

January 18, 2013

In Brief: Painter Is AMA President-Elect; FDA Approves Taxol; Protocol Enrolls 150-200 A Month

August 14, 1992

In Brief: Lobuglio Named Alabama Comprehensive Center Director; NCI FY 1983 Funds Will Be $983.6 Million

January 7, 1983

New Technology May Enable Therapy Tailored To Patient’s Predicted Response

April 26, 2002

Private Institute Commits $1 Million Pick Up some NIH Grants Left Unfunded

April 19, 1985